Jivi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Jivi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to factors such as the rising prevalence of hemophilia, increased investment in research and development, a focus on prophylactic treatments, global healthcare investments, and a higher rate of diagnoses.

The anticipated growth in the forecast period is driven by factors such as increased global healthcare expenditure, a growing male population, favorable government initiatives, rising awareness and early diagnosis, and a greater emphasis on personalized medicine. Key trends for the forecast period include technological advancements, the development of new hemophilia treatments, the increasing popularity of gene therapy, the ongoing creation of innovative treatments, and a shift towards therapies with extended half-lives.

The growing prevalence of hemophilia is expected to drive the expansion of the jivi market. Hemophilia is caused by genetic mutations in X-linked genes that are responsible for producing clotting factors, leading to deficiencies or defects in Factor VIII (hemophilia A) or Factor IX (hemophilia B), impairing the blood's ability to clot properly. The increasing incidence of hemophilia is partly due to advancements in diagnostic methods, greater awareness, and improved case reporting worldwide. Jivi assists hemophilia patients by providing a long-acting recombinant therapy that replaces the deficient Factor VIII, aiding blood clotting and preventing or controlling bleeding episodes. Its extended half-life reduces dosing frequency, improving patient convenience and adherence. For example, in 2022, new registrations for Hemophilia A in the UK increased from 16 in 2021 to 19, according to the United Kingdom Hemophilia Centre Doctor's Organization. Therefore, the rising prevalence of hemophilia is contributing to the growth of the jivi market.

The increasing emphasis on personalized medicine is expected to propel the growth of the jivi market. Personalized medicine tailors treatments to an individual's genetic makeup, environment, and lifestyle. Factors such as advancements in genomic medicine, rising chronic diseases, improved diagnostic tools, and a patient-centered healthcare approach are driving the demand for personalized treatments. Jivi serves as a personalized medicine solution for hemophilia A patients, as its extended half-life allows for customized dosing schedules, which improves adherence and reduces bleeding episodes. For example, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022, according to the Personalized Medicine Coalition. This growing focus on personalized medicine is fueling the growth of the jivi market.

Increased investment in research and development is expected to further accelerate the growth of the jivi market. These investments are driven by the need for innovative therapies that address unmet medical needs, improve treatment efficacy, and enhance patient outcomes across various medical areas. Investments in Jivi's research and development improve its efficacy, safety, and convenience, particularly through enhancements to its extended half-life, which supports less frequent dosing and better patient adherence. For example, in 2022, European governments allocated approximately $126.15 billion (€117.37 billion) for research and development, a 5.4% increase from 2021, according to Eurostat. Thus, the growing investment in research and development is contributing to the growth of the jivi market.

The key company operating in the jivi market is Bayer AG.

North America was the largest region in the jivi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in jivi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the jivi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Jivi is a recombinant factor VIII (antihemophilic factor) used to treat and prevent bleeding episodes in individuals with hemophilia A, a genetic disorder that affects blood clotting. It works by replacing the missing Factor VIII protein, which is crucial for blood clotting, and helps reduce the frequency of bleeding episodes when used as part of a prophylactic regimen. Jivi is known for its extended half-life, which allows fewer injections compared to traditional Factor VIII treatments, enhancing patient convenience and adherence.

The primary formulations available for jivi include lyophilized powder for reconstitution and ready-to-use formulations. The lyophilized powder is freeze-dried into a powder, which is then reconstituted with a solvent before administration. Jivi can be administered via intravenous or subcutaneous injection. It is used for various indications, including treating hemophilia A, providing prophylactic care, and offering on-demand treatment for bleeding episodes. Jivi is distributed through direct sales, wholesalers, distributors, and retail pharmacies. The key settings for its use include hospitals, hemophilia treatment centers, specialty clinics, and home healthcare environments.

The jivi market research report is one of a series of new reports that provides jivi market statistics, including jivi industry global market size, regional shares, competitors with a jivi market share, detailed jivi market segments, market trends, and opportunities, and any further data you may need to thrive in the jivi industry. This jivi market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The jivi market consists of sales of prophylactic dosing regimens and injectable formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values are revenues generated by organizations in the specified geography within the market irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.